[go: up one dir, main page]

MA41901A - Compositions contenant de l'ibrutinib - Google Patents

Compositions contenant de l'ibrutinib

Info

Publication number
MA41901A
MA41901A MA041901A MA41901A MA41901A MA 41901 A MA41901 A MA 41901A MA 041901 A MA041901 A MA 041901A MA 41901 A MA41901 A MA 41901A MA 41901 A MA41901 A MA 41901A
Authority
MA
Morocco
Prior art keywords
compositions containing
containing ibrutinib
ibrutinib
compositions
Prior art date
Application number
MA041901A
Other languages
English (en)
Inventor
Maristella Bernini
Dilip Gole
Manish Kumar Gupta
Sabine Inghelbrecht
Binuraj Krishnan Nair
Kaustubh Tambwekar
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806788&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA41901(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA41901A publication Critical patent/MA41901A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
    • B01J2/10—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic in stationary drums or troughs, provided with kneading or mixing appliances
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
    • B01J2/22—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by pressing in moulds or between rollers
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA041901A 2015-04-06 2016-04-06 Compositions contenant de l'ibrutinib MA41901A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562143659P 2015-04-06 2015-04-06

Publications (1)

Publication Number Publication Date
MA41901A true MA41901A (fr) 2021-04-14

Family

ID=55806788

Family Applications (2)

Application Number Title Priority Date Filing Date
MA54411A MA54411B1 (fr) 2015-04-06 2016-04-06 Compositions contenant de l'ibrutinib
MA041901A MA41901A (fr) 2015-04-06 2016-04-06 Compositions contenant de l'ibrutinib

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA54411A MA54411B1 (fr) 2015-04-06 2016-04-06 Compositions contenant de l'ibrutinib

Country Status (29)

Country Link
US (5) US20160287594A1 (fr)
EP (3) EP4272835A3 (fr)
JP (3) JP2018513852A (fr)
KR (2) KR20240013859A (fr)
CN (2) CN107530293A (fr)
AU (3) AU2016246669B2 (fr)
CA (1) CA2981601A1 (fr)
CL (1) CL2017002512A1 (fr)
DK (1) DK3892302T3 (fr)
EA (1) EA033992B1 (fr)
ES (1) ES2964472T3 (fr)
FI (1) FI3892302T3 (fr)
HK (1) HK1250925A1 (fr)
HR (1) HRP20231207T1 (fr)
HU (1) HUE063751T2 (fr)
IL (2) IL295941A (fr)
LT (1) LT3892302T (fr)
MA (2) MA54411B1 (fr)
MD (1) MD3892302T2 (fr)
MX (2) MX2017012822A (fr)
PH (1) PH12017501811A1 (fr)
PL (1) PL3892302T3 (fr)
PT (1) PT3892302T (fr)
RS (1) RS64653B1 (fr)
SG (2) SG10202103458QA (fr)
SI (1) SI3892302T1 (fr)
SM (1) SMT202300422T1 (fr)
UA (1) UA125681C2 (fr)
WO (1) WO2016164404A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201492082A1 (ru) 2012-06-04 2015-03-31 Фармасайкликс, Инк. Кристаллические формы ингибитора тирозинкиназы брутона
EP3193877A4 (fr) 2014-08-07 2018-04-04 Pharmacyclics LLC Nouvelles formulations d'un inhibiteur de la tyrosine kinase de bruton
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
MA54411B1 (fr) 2015-04-06 2023-11-30 Janssen Pharmaceutica Nv Compositions contenant de l'ibrutinib
CN109790121B (zh) 2016-10-06 2024-01-05 詹森药业有限公司 用于制备btk抑制剂的方法和中间体
WO2018167628A1 (fr) 2017-03-13 2018-09-20 Ftf Pharma Private Limited Composition pharmaceutique de suspension orale d'agents immunosuppresseurs
CN108653231A (zh) * 2017-04-01 2018-10-16 北京赛林泰医药技术有限公司 含有布鲁顿酪氨酸激酶抑制剂的组合物及其制备方法
CN107014943B (zh) * 2017-06-07 2018-08-21 福建省微生物研究所 一种依鲁替尼对映异构体的检测方法
WO2019038584A1 (fr) 2017-08-19 2019-02-28 Ftf Pharma Private Limited Composition pharmaceutique orale comprenant du zonisamide et son procédé de préparation
BR112020006039A2 (pt) 2017-09-26 2020-10-06 Tesaro, Inc. formulações de niraparibe
US11576917B2 (en) 2018-01-20 2023-02-14 Natco Pharma Limited Pharmaceutical compositions comprising Ibrutinib
KR20190122561A (ko) * 2018-04-21 2019-10-30 류형준 림프 순환 장애의 치료 또는 경감을 위한 약학적 조성물과 식품 조성물
CN112292117B (zh) 2018-06-15 2024-06-07 詹森药业有限公司 包含依鲁替尼的配制品/组合物
GB2591396B (en) * 2018-08-18 2023-06-07 Ftf Pharma Private Ltd Pharmaceutical suspension for oral dosage
WO2020039264A2 (fr) * 2018-08-18 2020-02-27 Ftf Pharma Private Limited Suspension pharmaceutique chimiothérapeutique pour forme galénique orale
KR102198502B1 (ko) * 2018-09-16 2021-01-05 류형준 인체의 림프순환 개선을 위한 식품 조성물
MX2021006368A (es) * 2018-11-30 2021-10-13 Janssen Biotech Inc Métodos para tratar el linfoma folicular.
US10688050B1 (en) 2018-12-21 2020-06-23 Synthon B.V. Pharmaceutical composition comprising ibrutinib
US20230227570A1 (en) 2020-05-08 2023-07-20 Genmab A/S Bispecific antibodies against cd3 and cd20
KR102251435B1 (ko) * 2020-11-09 2021-05-11 류형준 림프순환 촉진에 의한 부종 개선을 위한 식품 조성물
WO2022260667A1 (fr) * 2021-06-10 2022-12-15 Hikma Pharmaceuticals Usa Inc. Formes posologiques orales d'ibrutinib
US11433072B1 (en) * 2021-06-10 2022-09-06 Hikma Pharmaceuticals USA, Inc. Oral dosage forms of ibrutinib

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK607188A (da) 1987-11-02 1989-06-22 Merck & Co Inc Tablet indeholdende en phthalazineddikesyreforbindelse
US5994348A (en) 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
DE10201304A1 (de) 2002-01-15 2003-07-31 Infineon Technologies Ag Nichtflüchtige Halbleiter -Speicherzelle sowie zugehöriges Herstellungsverfahren
DE602006013114D1 (de) 2005-04-28 2010-05-06 Wyeth Corp Mikronisiertes tanaproget und zusammensetzungen damit
EP2526934B1 (fr) 2006-09-22 2015-12-09 Pharmacyclics LLC Inhibiteurs de la tyrosine kinase de bruton
US8809273B2 (en) 2007-03-28 2014-08-19 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
US8003309B2 (en) 2008-01-16 2011-08-23 International Business Machines Corporation Photoresist compositions and methods of use in high index immersion lithography
NZ604040A (en) 2010-06-03 2015-02-27 Pharmacyclics Inc The use of inhibitors of bruton’s tyrosine kinase (btk)
EP2771010A4 (fr) * 2011-10-19 2015-04-01 Pharmacyclics Inc Utilisation d'inhibiteurs de la tyrosine kinase de bruton (btk)
EA201492082A1 (ru) * 2012-06-04 2015-03-31 Фармасайкликс, Инк. Кристаллические формы ингибитора тирозинкиназы брутона
WO2014004707A1 (fr) * 2012-06-29 2014-01-03 Principia Biopharma Inc. Formulations comprenant de l'ibrutinib
EP3827863B1 (fr) * 2013-03-14 2023-06-07 Fisher & Paykel Healthcare Limited Support de cathéter ayant un orifice d'aspiration
TWI609012B (zh) 2013-04-28 2017-12-21 廣東東陽光藥業有限公司 氨基喹唑啉類衍生物及其鹽和使用方法
US9617432B2 (en) * 2013-08-12 2017-04-11 The Yokohama Rubber Co., Ltd. Primer composition
EP3033079B1 (fr) * 2013-08-12 2018-10-31 Pharmacyclics LLC Méthodes de traitement d'un cancer amplifié par her2
WO2015071432A1 (fr) * 2013-11-14 2015-05-21 Sandoz Ag Compositions pharmaceutiques à base d'ibrutinib
WO2015140709A1 (fr) 2014-03-19 2015-09-24 Novartis Ag Formes posologiques pharmaceutiques solides
AU2015296010A1 (en) 2014-08-01 2017-02-02 Pharmacyclics Llc Biomarkers for predicting response of DLBCL to treatment with a BTK inhibitor
EP3193877A4 (fr) * 2014-08-07 2018-04-04 Pharmacyclics LLC Nouvelles formulations d'un inhibiteur de la tyrosine kinase de bruton
CN104523695A (zh) * 2014-11-12 2015-04-22 广东东阳光药业有限公司 一种治疗过度增生性疾病的药物组合物
CN104407067B (zh) * 2014-11-17 2016-01-20 广东东阳光药业有限公司 依鲁替尼及其异构体的检测方法
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
MA54411B1 (fr) 2015-04-06 2023-11-30 Janssen Pharmaceutica Nv Compositions contenant de l'ibrutinib
AU2017268839A1 (en) 2016-05-27 2018-11-29 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat B-cell proliferative disorders

Also Published As

Publication number Publication date
UA125681C2 (uk) 2022-05-18
LT3892302T (lt) 2023-11-10
JP2024026087A (ja) 2024-02-28
MA54411B1 (fr) 2023-11-30
EA033992B1 (ru) 2019-12-17
US12364698B2 (en) 2025-07-22
JP2022031690A (ja) 2022-02-22
US20220211713A1 (en) 2022-07-07
FI3892302T3 (fi) 2023-11-03
PT3892302T (pt) 2023-11-15
MX2017012822A (es) 2018-06-13
BR112017021325A2 (pt) 2018-06-26
KR20240013859A (ko) 2024-01-30
EP3892302A1 (fr) 2021-10-13
CN107530293A (zh) 2018-01-02
MA54411A (fr) 2021-10-13
CL2017002512A1 (es) 2018-03-16
IL254695A0 (en) 2017-11-30
US20230263804A1 (en) 2023-08-24
HK1250925A1 (zh) 2019-01-18
IL254695B2 (en) 2023-02-01
IL295941A (en) 2022-10-01
MX2021015250A (es) 2022-01-24
US20160287594A1 (en) 2016-10-06
HUE063751T2 (hu) 2024-01-28
CN113546054A (zh) 2021-10-26
US20170252344A1 (en) 2017-09-07
EP3280446A1 (fr) 2018-02-14
RS64653B1 (sr) 2023-10-31
JP7438178B2 (ja) 2024-02-26
EP3892302B8 (fr) 2023-10-18
PH12017501811A1 (en) 2018-04-23
CA2981601A1 (fr) 2016-10-13
AU2021250925A1 (en) 2021-11-11
AU2021250925B2 (en) 2023-11-16
KR102632745B1 (ko) 2024-02-01
EA201792224A1 (ru) 2018-06-29
AU2024200883A1 (en) 2024-02-29
SG11201707989PA (en) 2017-10-30
DK3892302T3 (da) 2023-11-13
KR20170134582A (ko) 2017-12-06
AU2016246669B2 (en) 2021-07-15
IL254695B (en) 2022-10-01
AU2016246669A1 (en) 2017-10-12
JP2018513852A (ja) 2018-05-31
EP3892302B1 (fr) 2023-09-06
EP4272835A2 (fr) 2023-11-08
PL3892302T3 (pl) 2024-03-11
SMT202300422T1 (it) 2024-01-10
SG10202103458QA (en) 2021-05-28
HRP20231207T1 (hr) 2024-01-19
WO2016164404A1 (fr) 2016-10-13
SI3892302T1 (sl) 2023-11-30
MD3892302T2 (ro) 2024-03-31
US20200171036A1 (en) 2020-06-04
EP4272835A3 (fr) 2023-12-20
ES2964472T3 (es) 2024-04-08

Similar Documents

Publication Publication Date Title
MA41901A (fr) Compositions contenant de l'ibrutinib
EP3515467C0 (fr) Composition ophtalmique comprenant ciclosporine
FR3020060B1 (fr) Preparation d'imides contenant un groupement fluorosulfonyle
EP3040355A4 (fr) Modificateur d'asphalte et composition d'asphalte le contenant
EP3329915A4 (fr) Patch adhésif contenant de l'asénapine
EP3415008A4 (fr) Composition germicide
EP3315430A4 (fr) Contenant
EP3362038A4 (fr) Composition cosmétique contenant des bactéries probiotiques
EP3412344A4 (fr) Composition d'agent extincteur
MA49116A (fr) Compositions pharmaceutiques contenant de l'insuline
EP3360546A4 (fr) Composition solide contenant un polyphénol
EP3487902A4 (fr) Compositions de polyesterpolyol contenant du hfo-1336mzzm(z)
EP3610851A4 (fr) Composition d'agent nettoyant pour la peau
EP3704757A4 (fr) Composition d'électrolyte
MA44601A (fr) Composition ophtalmique contenant de la pvp-i
MA43764A (fr) Inhibiteur monovalent de l'interaction hutnfr1
EP3384782A4 (fr) Boisson contenant de l'hydroxytyrosol
EP3458432A4 (fr) Composition d'engrais
EP3416672A4 (fr) Formulations d'oritavancine
ES1109830Y (es) " senalador de prendas"
EP3520771A4 (fr) Composition anti-stress contenant de la cosmopérine
EP3315132A4 (fr) Patch d'absorption percutanée contenant de la nalfurafine
FR3029780B1 (fr) Composition comprenant de l'hesperetine
LT3096839T (lt) Kvapnios kompozicijos kūnui
EP3455306A4 (fr) Compositions d'encre